Seroatlas · Human Serome Atlas

CPN2

Carboxypeptidase N subunit 2

Also known as: ACBP, CPN2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P22792
Gene: CPN2
Ensembl: ENSG00000178772
Chromosome: 3
Canonical length: 545 aa
Protein class: Plasma proteins, Predicted secreted proteins
Secretome location: Secreted to blood

OverviewNCBI Gene

Predicted to enable enzyme regulator activity. Predicted to be involved in protein stabilization. Located in blood microparticle and extracellular exosome. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

545 residues, UniProt reviewed canonical sequence.

>P22792|CPN2
     1  MLPGAWLLWT SLLLLARPAQ PCPMGCDCFV QEVFCSDEEL ATVPLDIPPY TKNIIFVETS
    61  FTTLETRAFG SNPNLTKVVF LNTQLCQFRP DAFGGLPRLE DLEVTGSSFL NLSTNIFSNL
   121  TSLGKLTLNF NMLEALPEGL FQHLAALESL HLQGNQLQAL PRRLFQPLTH LKTLNLAQNL
   181  LAQLPEELFH PLTSLQTLKL SNNALSGLPQ GVFGKLGSLQ ELFLDSNNIS ELPPQVFSQL
   241  FCLERLWLQR NAITHLPLSI FASLGNLTFL SLQWNMLRVL PAGLFAHTPC LVGLSLTHNQ
   301  LETVAEGTFA HLSNLRSLML SYNAITHLPA GIFRDLEELV KLYLGSNNLT ALHPALFQNL
   361  SKLELLSLSK NQLTTLPEGI FDTNYNLFNL ALHGNPWQCD CHLAYLFNWL QQYTDRLLNI
   421  QTYCAGPAYL KGQVVPALNE KQLVCPVTRD HLGFQVTWPD ESKAGGSWDL AVQERAARSQ
   481  CTYSNPEGTV VLACDQAQCR WLNVQLSPQQ GSLGLQYNAS QEWDLRSSCG SLRLTVSIEA
   541  RAAGP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CPN2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.3
Highest tissue expression: 205 nTPM

Expression across tissuesHPA

Tissue

liver: 205 nTPM
kidney: 14 nTPM
adrenal gland: 2.9 nTPM
bone marrow: 1.4 nTPM
spleen: 1.1 nTPM
retina: 1 nTPM

Single-cell type

hepatocytes: 204 nCPM
hepatic stellate cells: 13 nCPM
kupffer cells: 3.1 nCPM
proximal tubule cells: 2.6 nCPM
mucous neck cells: 1.6 nCPM
adrenal cortex cells: 1.3 nCPM

Immune cell

neutrophil: 0.4 nTPM
naive CD8 T-cell: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM

Brain region

cerebral cortex: 8.6 nTPM
white matter: 8.6 nTPM
hypothalamus: 8.2 nTPM
basal ganglia: 7.9 nTPM
cerebellum: 7.5 nTPM
thalamus: 7.4 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.97
gnomAD pLI: 0
gnomAD missense Z: 0.29
DepMap mean gene effect: -0.03
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

protein stabilization

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CPN2 as an antibody target. Whether an autoantibody or antibody against CPN2 could matter depends on whether native CPN2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CPN2 is annotated as secreted, so native CPN2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label CPN2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...